Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 1998

View Archived Issues

Alexion: Q4 1998 highlights

Xenotransplanted human dopaminergic cells improve motor deficits in MPTP-treated monkeys

Roche: Q3 1998 highlights

Shionogi: Annual Report 1998

Simulect gets the go-ahead from the European Commission

Potent antitumor activity, low toxicity observed in in vitro studies of aplidine

SR-121787: the most potent fibrinogen antagonist reported to date

Potent GABA-B antagonists described for CNS disorders by Novartis

Monosaccharide conjugates of pyrimethamine and other therapeutic agents patented

New series of antiischemic/antiarrhythmic compounds developed at HMR

New compounds from Astra for pain, GI disorders and spinal injuries

Potent new PDE5 inhibitor with potential clinical utility

Antiulcer angucycline compound isolated from Streptomyces

Fournier characterizes potent and selective human bradykinin B2 antagonist in vitro

Takeda discontinues further development of osteoporosis drug

Antibacterial ointment preparation for periodontitis will be codeveloped by Toyama and Showa

Efficacy and safety demonstrated for rasagiline as adjunct to levodopa in PD

Botulinum toxin type F useful in type A-resistant patients with dystonia

Effects of DX-9065a on platelet activation reported at international congress

Platelet collagen receptors targeted for development of new antiplatelet therapies

Phase III trial of Nutropin Depot successfully completed; NDA filing slated for 1999

Tacalcitol lotion equivalent to ointment in animal study

Roche granted additional exclusivity for Versed from FDA

Potent new antibiotic isolated from soil microorganism undergoes further evaluation

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...